SLC22A6 and metabolic syndrome: This work not only highlights the potential of OAT1 in the modulation of systemic lipid metabolism and signaling, but, as we show, it also provides insight into certain drug-induced dyslipidemias such as those seen with chronic treatment with OAT1-transported diuretics or antiviral cocktails (29).